KHK4951 eye drops maintained vision in most nAMD patients at 52 weeks
KHK4951 eye drops maintained vision in 65-69% of Phase 2 patients with nAMD without rescue injections at 52 weeks, with stable safety and tolerability, per the source.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.